# VIATRIS INC. (VTRS) · Edgar & Edgarette company card

> Viatris (VTRS) saw revenue fall 3.0% in FY2025 to $14.3 billion, operating margin -18.6% against a -3.8% median for pharmaceutical preparations, equity 39.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1792044 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VTRS) · [JSON](https://www.pops4.com/boards/company/VTRS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $14.3B |
| Revenue growth, 1 year | -3.0% |
| Revenue growth per year | -5.4% |
| Operating margin | -18.6% (prior year 0.1%) |
| Net margin | -24.6% |
| Operating cash flow | $2.3B |
| Capital spending | $379M |
| Free cash flow | $1.9B |
| Cash | $1.3B |
| Long-term debt | $14.4B |
| Total assets | $37.2B |
| Total equity | $14.7B |
| Equity ÷ assets | 39.6% |
| Return on equity | -23.9% |
| Dividend per share | $0.48 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: 0.65 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -3.27 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · filed restructuring or exit costs in the last 12 months; operating loss: a margin of -18.6% in FY2025
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $14.3B (FY2025), total debt $14.4B. Experience: revenue down 3.0% on the year, down 5.4% a year over 4 years; operating margin -18.6%, down from 0.1%. Soundness: equity 39.6% of assets, return on equity -23.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $12.4B and $14.3B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $11.7B to $15.1B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -18.6% against a -3.8% median; growth -3.0% against 13.7%.

Range logged 2026-10-09, receipt f0594844b5ab0e15, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-02-26 ([filing](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/0001792044-26-000010-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-05-04 ([filing](https://www.sec.gov/Archives/edgar/data/1792044/000114036126018887/0001140361-26-018887-index.htm))

## Recent filings

- 8-K · filed 2026-11-17 · 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1792044/000114036126044356/0001140361-26-044356-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000057/0001792044-26-000057-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/0001792044-26-000053-index.htm)
- 8-K · filed 2026-10-08 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1792044/000114036126039024/0001140361-26-039024-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/0001792044-26-000041-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/0001792044-26-000037-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001792044.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1792044

## Cite

POPS4, Edgar & Edgarette: VIATRIS INC. (VTRS) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/VTRS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

